Breast/ovarian cancer
101 – 110 of 150
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Detection of Copy Number Aberration and Tumor Fraction in Archival Cervical Specimens from Ovarian Cancer Patients using Shallow Whole Genome Sequencing.
(2021)
- Contribution to conference › Poster
-
Mark
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
- Contribution to journal › Article
-
Mark
Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study
- Contribution to journal › Article
-
Mark
Regulatory T lymphocyte infiltration in metastatic breast cancer—an independent prognostic factor that changes with tumor progression
- Contribution to journal › Article
-
Mark
Protein signature predicts response to neoadjuvant treatment with chemotherapy and bevacizumab in HER2-negative breast cancers
- Contribution to journal › Article
- 2020
-
Mark
Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer
- Contribution to journal › Article
-
Mark
Defining the mutational landscape of 3,217 primary breast cancer transcriptomes through large-scale RNA-seq within the Sweden Cancerome Analysis Network: Breast Project (SCAN-B; NCT03430492).
- Contribution to journal › Published meeting abstract
-
Mark
Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
- Contribution to journal › Article
-
Mark
Fine-tuning the metabolic rewiring and adaptation of translational machinery during an epithelial-mesenchymal transition in breast cancer cells
- Contribution to journal › Article
-
Mark
Analysis of fusion transcripts indicates widespread deregulation of snoRNAs and their host genes in breast cancer
- Contribution to journal › Article
